Navigation Links
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Date:5/12/2008

can identify which patients may benefit from 400IU of natural vitamin E. Administration of this dose and type of vitamin E led to a 50% reduction in non-fatal myocardial infarction in the ICARE study, reported earlier this year. The test is being developed to be used on current ubiquitous laboratory platforms (e.g., ELISA), and also to be used in genetic testing labs. The test is also being developed such that it will apply to CMS parameters for reimbursement. Once available, the Company plans to distribute the test to hospitals and other independent labs that have high volume customers.

To bring the most effective therapy to patients who will benefit most, Synvista has developed an extensive intellectual property portfolio based on utilizing haptoglobin genotyping or phenotyping to target the use of drugs in diabetic individuals with the Hp 2-2 genotype, thereby creating an unique product portfolio that both identifies a specific patient profile and provides therapeutic solutions to address patients' needs.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics is also developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing marke
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... York (PRWEB) March 05, 2015 LifeCell ... to be able to get an Advanced Semen Analysis ... stress, blaming and guessing are all risk factors for ... the woman is the source of the infertility. Infertility ... LifeCell Dx has the simplest, least complicated and ...
(Date:3/5/2015)... Triangle Park, NC (PRWEB) March 05, 2015 ... Inc., announced that Pierre Noel, M.D., Professor of ... elected to the Company’s Board of Directors. ... said, “We are extremely fortunate to have Dr. ... the country’s leading healthcare organization, join Entegrion’s Board. ...
(Date:3/5/2015)... 5, 2015  In response to the incorrect assertions ... FL on February 12, 2015. Impeto Medical ... financial health and their SUDOSCAN® devices have been proven ... Impeto prefers to have the courts decide this dispute ... than 40 articles written by Key Opinion Leaders, published ...
(Date:3/4/2015)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 3.75% Convertible Senior Notes due May 1, 2015 ... $1,000 principal amount or approximately $5.72 per share, effective March 3, ... is adjusted in connection with the regular quarterly dividend of ... who own shares of PDL on March 5, 2015, the record ...
Breaking Biology Technology:LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... June 21, 2011 Ikaria, Inc., a critical care ... to address the significant needs of critically ill patients ... its Chairman and CEO, Daniel Tasse, will present at ... International Convention on Tuesday, June 28, 2011 from 2:30 ...
... 2011 Merisel, Inc. (OTC: MSEL) operating under ... , a leading provider of visual communications and brand imaging ... last night at the 9th Annual American Business Awards Ceremony, ... its commitment to delivering solid results, despite prevailing economic turbulence. ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ... targeting the extracellular matrix , today announced ... programs at the American Diabetes Association (ADA) ... 2011 at the San Diego Convention Center. ...
Cached Biology Technology:Ikaria® To Present at 2011 BIO Business Forum and International Convention 2Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 2Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 3Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 4Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 5Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions 2Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions 3
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/10/2015)...  Alere Inc. (NYSE: ALR), a global leader ... the quarter ended December 31, 2014. ... Alere said, "We made substantial progress in the ... leader in rapid diagnostics and delivering against our ... in early January enabled us to substantially reduce ...
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... Three University of Idaho researchers will embark on an unconventional ... nationwide by federal officials for the ideas to explore scientific ... who are both 32, were the youngest researchers chosen among ... of Idaho team by a senior scientist, growth biology Prof. ...
... The world,s last remaining "pristine" forest the ... other northern countries is under increasing threat, a ... from Memorial University of Newfoundland in Canada, University of ... have called for the urgent preservation of existing boreal ...
... crying is known to be a symptom of physical ... evolutionary biologist looks to empirical evidence showing that tears ... New analysis by Dr. Oren Hasson of TAU,s ... distress, but they also function as an evolution-based mechanism ...
Cached Biology News:Idaho researchers win grant to explore DNA frontier 2World's last great forest under threat: New study 2Trust in a teardrop 2
... RED Chromogen System consists of FAST RED ... in the presence of alkaline phosphatase to ... The FAST RED System provides enough ... Contains: , , Vial A: 6 Tablets ...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... stain kits are optimized for use ... Dodeca stainers. This silver stain kit ... in polyacrylamide gels and are mass ... concentrate, silver reagent concentrate, background reducer ...
... and 96 well plates. microCLEAN is an extremely ... half spin DNA cleanup reagent. It can be ... of double stranded DNA, efficiently removing reaction buffers, ... unlabelled). It is therefore ideally suited to clean ...
Biology Products: